BlackRock
SLN

BlackRock’s Silence Therapeutics SLN Stock Holding History

BlackRock’s Portfolio SLN Stock Details SLN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.41M Buy
219,917
+15,140
+7% +$107K ﹤0.01% 4114
2026
Q1 		$1.08M Buy
204,777
+131,624
+180% +$725K ﹤0.01% 4322
2025
Q4 		$445K Buy
73,153
+11,321
+18% +$72.5K ﹤0.01% 4508
2025
Q3 		$321K Sell
61,832
-106,403
-63% -$591K ﹤0.01% 4573
2025
Q2 		$976K Sell
168,235
-12,200
-7% -$52.3K ﹤0.01% 4258
2025
Q1 		$509K Sell
180,435
-31,072
-15% -$152K ﹤0.01% 4395
2024
Q4 		$1.46M Buy
+211,507
New +$2.73M ﹤0.01% 4127

Other funds holding SLN

SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

BlackRock's SLN Position: Q2 2026 in Review

BlackRock increased its Silence Therapeutics (SLN) stake by 7.4% in Q2 2026, buying an estimated $107K and bringing the position to 219,917 shares worth $2.41M. The position accounts for ﹤0.01% of the portfolio, ranked #4114.

BlackRock first reported a position in SLN in Q4 2024 and has held it in 7 quarters since. 72 funds tracked by Wall St. Rank hold SLN as of Q2 2026.

  • BlackRock held 219,917 shares of Silence Therapeutics worth $2.41M as of Q2 2026.
  • BlackRock bought 15,140 Silence Therapeutics shares in Q2 2026, an estimated $107K.
  • Silence Therapeutics made up ﹤0.01% of BlackRock's portfolio in Q2 2026, its #4114 holding.
  • BlackRock first reported a position in Silence Therapeutics in Q4 2024 and has held it in 7 quarters since.
  • 72 funds tracked by Wall St. Rank held Silence Therapeutics as of Q2 2026.

Based on BlackRock's 13F filing for Q2 2026, filed 7 Aug 2026.